Interferon decreases VEGF levels in patients with chronic myeloid leukemia treated with imatinib

Leukemia Research

Volumn 38, Issue 6, 2014, Pages 662-665

  Legros, L ^a,b   Guilhot, J ^c   Huault, S ^b   Mahon, F X ^d   Preudhomme, C ^e   Guilhot, F ^c   Hueber, A O ^b  

^a Service d'Hématologie Clinique HÔpital Archet 1   (France)

^b CNRS   (France)

^c POITIERS UNIVERSITY HOSPITAL   (France)

^d BORDEAUX UNIVERSITY HOSPITAL   (France)

^e LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Angiogenesis; Chronic myeloid leukemia (CML); Imatinib; Interferon alpha; Vascular Endothelial Growth Factor (VEGF)

Indexed keywords

CYTARABINE; IMATINIB; PEGINTERFERON ALPHA2A; VASCULOTROPIN;

ADULT; AGE; AGED; ARTICLE; BLOOD; BONE MARROW; CHROMOSOME ABERRATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG DOSE COMPARISON; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SOKAL RISK SCORE; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTE COUNT;

ANGIOGENESIS; CHRONIC MYELOID LEUKEMIA (CML); IMATINIB; INTERFERON-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF);

ADULT; AGED; AGED, 80 AND OVER; BENZAMIDES; FEMALE; HUMANS; INTERFERONS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84900395056     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2014.01.010     Document Type: Article

References (21)

1. Sawyers C.L. Chronic myeloid leukemia. N Engl J Med 1999, 340:1330-1340.
2. Konopleva M., Tabe Y., Zeng Z., Andreeff M. Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches. Drug Resist Update 2009, 12:103-113.
3. Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 2002, 29:10-14.
4. Hatfield K., Ryningen A., Corbascio M., Bruserud O. Microvascular endothelial cells increase proliferation and inhibit apoptosis of native human acute myelogenous leukemia blasts. Int J Cancer 2006, 119:2313-2321.
5. Aguayo A., Kantarjian H., Manshouri T., Gidel C., Estey E., Thomas D., et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 2000, 96:2240-2245.
6. Dias S., Hattori K., Zhu Z., Heissig B., Choy M., Lane W., et al. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest 2000, 106:511-521.
7. Korkolopoulou P., Viniou N., Kavantzas N., Patsouris E., Thymara I., Pavlopoulos P.M., et al. Clinicopathologic correlations of bone marrow angiogenesis in chronic myeloid leukemia: a morphometric study. Leukemia 2003, 17:89-97.
8. Legros L., Bourcier C., Jacquel A., Mahon F.X., Cassuto J.P., Auberger P., et al. Imatinib mesylate (STI571) decreases the vascular endothelial growth factor plasma concentration in patients with chronic myeloid leukemia. Blood 2004, 104:495-501.
9. Preudhomme C., Guilhot J., Nicolini F.E., Guerci-Bresler A., Rigal-Huguet F., Maloisel F., et al. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med 2010, 363:2511-2521.
10. Baccarani M., Cortes J., Pane F., Niederwieser D., Saglio G., Apperley J., et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009, 27:6041-6051.
11. Fiedler W., Graeven U., Ergun S., Verago S., Kilic N., Stockschlader M., et al. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood 1997, 89:1870-1875.
12. Bellamy W., Richter L., Sirjani D., Roxas C., Glinsmann-Gibson B., Frutiger Y., et al. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood 2001, 97:1427-1434.
13. Verstovsek S., Kantarjian H., Manshouri T., Cortes J., Giles F.J., Rogers A., et al. Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia. Blood 2002, 99:2265-2267.
14. Nicolini F.E., Hayette S., Legros L., Rousselot P., Maloisel F., Tulliez M., et al. Pegylated IFN-alpha2a combined to imatinib mesylate 600mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600mg daily alone. Leuk Res 2011, 35:80-86.
15. Marin D.F., Ibrahim A.R., Ibrahim A.F., Lucas C., Lucas C.F., Gerrard G., et al. Clark RE assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol 2012, 30:232-238.
16. Ohm L.F., Arvidsson I., Arvidsson I.F., Barbany G., Barbany G.F., Hast R., et al. Early landmark analysis of imatinib treatment in CML chronic phase: less than 10% BCR-ABL by FISH at 3 months associated with improved long-term clinical outcome. Am J Hematol. Am J Hematol 2012, 87:760-765.
17. von Marschall Z., Scholz A., Cramer T., Schafer G., Schirner M., Oberg K., et al. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst 2003, 95:437-448.
18. Simonsson B., Gedde-Dahl T., Markevarn B., Remes K., Stentoft J., Almqvist A., et al. Combination of pegylated IFN-alpha2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia. Blood 2012, 118:3228-3235.
19. Talpaz M., Hehlmann R., Quintas-Cardama A., Mercer J., Cortes J. Re-emergence of interferon-alpha in the treatment of chronic myeloid leukemia. Leukemia 2012, 27:803-812.
20. Hsu Y.C., Fuchs E. A family business: stem cell progeny join the niche to regulate homeostasis. Nat Rev Mol Cell Biol 2012, 13:103-114.
21. Wang L.D., Wagers A.J. Dynamic niches in the origination and differentiation of haematopoietic stem cells. Nat Rev Mol Cell Biol 2011, 12:643-655.